LFVN
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

LifeVantage Corporation is a nutrigenomics company that identifies, researches, develops, formulates, and sells dietary supplements, weight management products, gut health products, skin and hair care products, and nootropics. The company operates through a direct sales model, providing products to customers and independent consultants in the United States, Canada, Mexico, Japan, Taiwan, Thailand, Australia, New Zealand, and various European countries including the United Kingdom, Germany, Spain, and Portugal. Its product portfolio includes the flagship Protandim line, the LifeVantage line featuring the MindBody GLP-1 System and Omega+, the TrueScience skin and hair care line, the P84 System for gut health, Petandim for companion pets, and AXIO nootropic and energy drink mixes. Incorporated in 1988 as Andraplex Corporation, the company changed its name to Yaak River Resources in 1992, Lifeline Therapeutics in 2004, and LifeVantage Corporation in 2006. In 2018, it reincorporated in Delaware. The company transitioned from a traditional retail model to a direct sales model in 2008 and acquired the operating assets of LoveBiome in 2025 to expand its gut health offerings.

Summarised from the company's own disclosures, fiscal year ended Aug 2026

Industry Household & Personal Products Homepage lifevantage.com
Sector Consumer Defensive IR page investor.lifevantage.com
Tags
nutrigenomics, dietary supplements, direct sales, gut health, nootropics, skin care, weight management, cellular health, pet supplements, energy drinks, Protandim, LifeVantage, MindBody GLP-1 System, Omega+, ProBio, IC Bright, Rise AM & Reset PM System, D3+, Daily Wellness, Fat Burn, Prebiotic, Carb Block, TrueScience, Liquid Collagen, P84 System, PhytoPower 1, PhytoPower 2, PhytoPower B, Petandim, AXIO, AXIO X, AXIO Hydrate, AXIO Smart Energy, TrueRefine Glow-Up Mask, MB System, MB Core, MB Enhance, Healthy Edge, Protandim Nrf2 Synergizer, LoveBiome
Press page —

Metrics

Valuation  
Market cap $ 61.511M
Market cap (USD) $ 61.511M
P/E 23.27
PEG 0.90
P/BV 1.85
P/S 0.36
P/OCF 4.70
P/FCF 7.06
Dividend yield 0.61%
Turnover / mcap —
Returns  
ROE 14.9%
ROI 19.1%
ROIC 19.2%
Profit margin 2.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 25.9%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score 10.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008
Revenue 182.586M 228.53M 200.164M 213.398M 206.36M 220.181M 232.915M 225.958M 203.204M 199.489M 206.54M 190.336M 213.968M 208.178M 126.183M 38.919M 4.141M 3.2M
Net profit 5.072M 9.805M 2.937M 2.54M 3.12M 12.894M 11.549M 7.429M 5.761M 1.608M 6.019M 6.987M 11.383M 7.608M 12.469M -50.792M -9.115M -2.054M
Free cash flow 6.67M 10.507M 9.952M 3.761M 6.429M 12.532M 15.645M 15.283M 8.607M 5.542M 5.424M 12.062M 10.207M 5.582M 17.195M 4.559M -5.434M -759.585K

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008
Share price 6.24 13.08 6.42 4.35 4.35 7.35 13.52 12.98 6.36 4.33 13.6 0.53 1.44 2.32 2.78 — 0.2 —
Price performance 12m -0.52 1.04 0.48 0 -0.41 -0.46 0.04 1.04 0.47 -0.68 24.68 -0.63 -0.38 -0.16 — — — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 1.33M 2.07M 2.07M 2.61M 2.93M 3.34M 1.61M 2.95M 3.29M 2.99M
↳ YoY growth -14.0% +54.9% 0.0% +26.3% +12.1% +14.1% -51.7% +82.9% +11.7% -9.2%
↳ 5y CAGR +32.0% +2.9% +9.4% +20.4% +13.5% +20.1% -4.9% +7.4% +4.8% +0.4%
Borrowings, current (USD) 2M 2M 1.45M 0.00 — — — — — —
Borrowings, non-current (USD) 5.44M 3.41M 0.00 — — — — — — —
Lease liabilities (USD) — — 3.9M 1.18M 18.2M 15.8M 13.1M 13.6M 11.7M 9.87M
Cash and deposits (USD) 11.5M 16.7M 18.8M 22.1M 23.2M 20.2M 21.6M 16.9M 20.2M 14.9M
Intangible assets (USD) 1.25M 1.12M 983,000 851,000 719,000 587,000 455,000 323,000 245,000 3.06M
Right-of-use assets (USD) — — 3.3M 956,000 13.7M 11M 8.74M 9.57M 8.04M 6.72M
Net debt (borrowings + leases - cash) (USD) -4.02M -11.2M -17.4M -21M — — — — — —
Cash flow detail
Operating cash flow (USD) 6.6M 13.3M 17.8M 18.3M 16.3M 7.96M 6.83M 12.2M 11.9M 10.2M
Purchases of property, plant and equipment (USD) -1.06M -4.65M -2.51M -2.68M -3.74M -1.53M -3.07M -2.25M -1.37M -3.57M
Change in receivables (cash effect) (USD) 160,000 -730,000 14,000 -539,000 -265,000 -614,000 1.56M -1.42M -242,000 200,000
Change in inventories (cash effect) (USD) 8.31M 2.95M -64,000 -152,000 -2.07M -1.19M 61,000 662,000 -5.22M 2.02M
Change in payables (cash effect) (USD) -6.21M -1.02M 1.37M -1.65M 3.21M 824,000 -3.98M 2.3M -1.3M 588,000
Dividends paid (cash effect) (USD) — — — 0.00 0.00 -378,000 -1.59M -6.94M -2.07M -2.34M
Share buybacks (cash effect) (USD) 0.00 -1.5M -4.66M -5.41M -11.9M -8.83M -800,000 -6.43M -3.15M -2.04M
Interest paid (cash effect) (USD) -438,000 -345,000 -227,000 -44,000 -17,000 -10,000 -5,000 -21,000 -2,000 -11,000
Income taxes paid (cash effect) (USD) -5.5M -2.87M -1.29M -1.62M -4.02M -2.6M -1.87M -2.31M -4.92M -995,000
Share-based compensation (USD) 2.65M 3.2M 5.53M 4.92M 2.04M 1.77M 3.19M 3.28M 5.7M 2.35M
Operating cash flow before change in receivables (USD) 6.44M 14M 17.8M 18.9M 16.5M 8.57M 5.27M 13.6M 12.1M 10M
Free cash flow (OCF - PPE - intangibles) (USD) 5.54M 8.61M 15.3M 15.6M 12.5M 6.43M 3.76M 9.95M 10.5M 6.67M
Income detail
Research and development expense (USD) 1.1M 1.2M 1.1M 900,000 700,000 700,000 600,000 700,000 1.4M 1M
↳ 5y CAGR -4.1% -16.5% -11.3% -17.8% -6.9% -8.6% -12.9% -8.6% +9.2% +7.4%
Total comprehensive income (USD) 1.52M 5.87M 7.48M 11.6M 12.9M 1.89M 2.3M 2.38M 10.5M 4.37M
Comprehensive income to owners (USD) — — — — — — — — 10.5M 4.37M
Provision for credit losses (USD) 0.00 0.00 0.00 0.00 0.00 0.00 100,000 0.00 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 4.0% 0.0% 0.0% 0.0%
Reported Sep 7, 2017 Aug 15, 2018 Oct 30, 2019 Aug 23, 2022 Aug 23, 2022 Aug 23, 2022 Aug 28, 2023 Aug 28, 2024 Aug 27, 2026 Aug 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Salt Lake City, UT, November 9, 2026, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its quarter ended September 30, 2026.

First Quarter Fiscal 2027 Summary*:

•Revenue was $37.1 million, a decrease of 22.0% from the prior year period;

•Revenue in the Americas decreased 22.2%, and revenue in Asia/Pacific & Europe decreased 21.2%;

•Net loss per diluted share was $0.02, versus net income per diluted share of $0.17 a year ago;

•Adjusted earnings per diluted share was $0.05, compared to $0.18 a year ago; and

•Adjusted EBITDA was $1.9 million compared to $3.9 million a year ago.

* All comparisons are on a year over year basis and compare the first quarter of fiscal 2027 to the first quarter of fiscal 2026, unless otherwise noted.

“Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it,” said Terrence Moorehead, President and Chief Executive Officer.

LifeVantage Corporation (the “Company”) held its fiscal year 2027 annual meeting of stockholders on November 5, 2026 (the “Annual Meeting”). Of the 12,589,444 shares of the Company’s common stock outstanding as of the record date, 9,421,295 shares, or 74.83% were represented at the Annual Meeting either in person or by proxy. The following proposals were submitted to a vote of the Company’s stockholders at the Annual Meeting: 1. To elect the following six director nominees to the Company’s board of directors to hold office until the next annual meeting of stockholders or until their respective successors are elected and qualified:

Mr. Rajendran Anbalagan

Mr. Darwin K. Lewis

Mr. Michael A. Beindorff

Mr. Terrence Moorehead

Mr. Raymond B. Greer

Mr. Dayton Judd

2. To approve, on an advisory basis, a resolution approving the compensation of the Company’s named executive officers; and 3. To ratify the selection of Deloitte & Touche, LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending June 30, 2027.

October 29, 2026 at 4:05 PM EDT

Download PDF

SALT LAKE CITY, Oct. 29, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN) continues to lead the next generation of healthy aging with its latest in vitro research study examining how five modern environmental toxins—pollution, microplastics, ultra-processed foods, hormone disruptors, and pesticides—affect cells and the role Protandim® Nrf2 can play in helping protect against their impact.† These findings further reinforce LifeVantage’s position as a pioneer in nutrigenomics and the science behind its products that ignite the human body’s natural defense systems.

“Modern life exposes people to things they cannot always see or avoid. Our work begins with a powerful belief: the body has remarkable systems designed to defend itself,” said LifeVantage CEO, Terrence Moorehead. “This research advances our understanding of how Protandim® Nrf2 can support those natural capabilities so people can continue living fully.”*

Making Cellular Stress Visible A two-part cell study was designed to further evaluate the beneficial effects of Protandim® Nrf2 on oxidative stress associated with modern toxins encountered in everyday life: microplastics, pollution (fine particulate matter), hormone disruptors (phthalates), pesticides (glyphosate), and ultra-processed foods and diet (methylglyoxal).

Three cell types—from the liver (HepG2), skin and connective tissue (Fibroblasts), and intestinal lining (Caco-2)—were selected to create a multi-tissue exposure platform based on their roles in the body’s defenses against toxin exposure. Each cell type was evaluated under three conditions: without toxin exposure, with toxin exposure, and with toxin exposure combined with Protandim® Nrf2.

“When people hear 'oxidative stress' or ‘environmental toxins,’ they often picture something far removed from their own lives like industrial factories or farming equipment,” said Lisa Barnes, Vice President of Research and Development at LifeVantage. “We wanted to study exposures that feel familiar and modern: the air around us, the foods we eat, and the products we use. What excites me about these findings is the possibility of empowering the human body to meet those everyday challenges by activating the powerful defenses it already has within.”*†

The Results The researchers evaluated cell viability and used fluorescent imaging to make oxidative stress visible, with more green indicating a higher oxidative stress signal and less green indicating a lower signal.

The viability data showed that all five tested environmental toxins adversely affected the three cell types: higher exposure levels caused cell death, while lower levels caused considerable cellular damage. Across all five categories, cells exposed to the toxins and then to Protandim® Nrf2 showed significantly lower oxidative stress signals than cells exposed to the stressor alone. In some cases, these signals returned to levels comparable to those observed in unexposed cells.*†

Example: Microplastics in HepG2

Example: Microplastics in HepG2

These findings suggest that Protandim® Nrf2 can help support cellular defenses against oxidative stress associated with the tested environmental toxins.*† The research does not demonstrate that the product removes toxins or prevents exposure but shows how cells responded under controlled laboratory conditions.

The new findings add to previous human clinical research showing that Protandim® Nrf2 reduced a marker of oxidative stress by an average of 40% after 30 days.††*

Read the full study atLifeVantage.com

Bringing the Science to Everyday Life Alongside the research, LifeVantage launched Cell Care, a new campaign designed to make cellular health more personal, visible and easy to understand. As part of the campaign, the new Cellular Stress Quiz asks 15 simple questions about everyday habits and potential exposures. Participants receive an educational Modern Life Exposure Score and information about supporting the body’s natural cellular defenses.*

“Cell Care turns complex science into a simple, personal question: What is your everyday routine asking of your cells?” said Wendy Freedman, Vice President of Global Marketing at LifeVantage. “The quiz helps people recognize exposures they may never have considered and gives them an easy way to start a conversation about supporting their bodies from within. Ultimately, it is about helping people make proactive choices and live healthier, longer.”*

Prompts

Lifevantage Corporation (ticker LFVN), listed in United States.

Company History

Date Change Detail
Dec 15, 2006 Renamed LIFELINE THERAPEUTICS, INC. → LIFEVANTAGE CORP
Oct 28, 2004 Renamed YAAK RIVER RESOURCES INC → LIFELINE THERAPEUTICS, INC.

ETFs Holding Lifevantage Corporation

ETF Weight in ETF Shares Market value As of
SQLV 0.19% 8,744 $ 54.563K Jun 30, 2026
IVSS 0.01% 615 $ 3,837.60 Jun 30, 2026
DFAS 0.00% 82,516 $ 415.881K Nov 12, 2026
DXUV 0.00% 7,128 $ 35.925K Nov 12, 2026
DFUS 0.00% 16,797 $ 84.657K Nov 12, 2026
DFAC 0.00% 34,338 $ 173.064K Nov 12, 2026
DCOR 0.00% 11,327 $ 57.088K Nov 12, 2026
AVUS 0.00% 6,080 $ 29.002K Nov 16, 2026
AVUV 0.00% 225,354 $ 1.075M Nov 16, 2026
AVSC 0.00% 16,662 $ 79.478K Nov 16, 2026
BSVO 0.00% 23,524 $ 110K Nov 18, 2026